Teva Pharmaceutical Industries
- Country
- 🇮🇱Israel
- Ownership
- -
- Employees
- 37.8K
- Market Cap
- $21.2B
- Introduction
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
Clinical Trials
139
Trial Phases
3 Phases
Drug Approvals
8
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (78 trials with phase data)• Click on a phase to view related trials
A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Pharmaceutical Industries, Ltd.
- Target Recruit Count
- 65
- Registration Number
- NCT02092077
- Locations
- 🇧🇾
Teva Investigational Site 68016, Minsk, Belarus
🇧🇬Teva Investigational Site 59060, Varna, Bulgaria
🇬🇪Teva Investigational Site 81022, Tbilisi, Georgia
TL011 in Severe, Active Rheumatoid Arthritis Patients
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2010-05-14
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- Teva Pharmaceutical Industries, Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT01123070
- Locations
- 🇨🇿
Teva Investigational Site 5428, Plzen, Czechia
🇨🇿Teva Investigational Site 5426, Prague 2, Czechia
🇨🇿Teva Investigational Site 5429, Uherske Hradiste, Czechia
An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Teva Pharmaceutical Industries, Ltd.
- Target Recruit Count
- 257
- Registration Number
- NCT00745615
- Locations
- 🇨🇿
Teva Investigational Site 382, Hradec Kralove 3, Czechia
🇨🇿Teva Investigational Site 380, Praha 2, Czechia
🇨🇿Teva Investigational Site 384, Praha 5- Motol, Czechia
Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: 40 mg glatiramer acetateDrug: Placebo
- First Posted Date
- 2006-05-17
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Teva Pharmaceutical Industries, Ltd.
- Target Recruit Count
- 366
- Registration Number
- NCT00326625
- Locations
- 🇧🇪
Teva Benelux, Leuven, Belgium
🇫🇷Teva France, Paris, France
🇩🇪Teva Germany, Morfelden-Walldorf, Germany
News
FDA Approves AJOVY as First CGRP Antagonist for Pediatric Migraine Prevention
Teva Pharmaceutical Industries received FDA approval for AJOVY as the first CGRP antagonist indicated for preventive treatment of episodic migraine in children and adolescents aged 6-17 weighing at least 45 kilograms.
German Federal Patent Court Revokes Key Xarelto Patent, Opening Door for Generic Competition
The German Federal Patent Court revoked Bayer's crucial Xarelto patent EP 1 845 961 due to lack of inventive step, contradicting its earlier 2024 opinion that assumed the patent's validity.
Leveragen and Propeller Bio Form Strategic Partnership to Advance Next-Generation Antibody Discovery Platform
Leveragen, a Boston-based biotech company, has announced a strategic collaboration with newly launched Propeller Bio to advance antibody and protein-based therapeutics development.
Vor Bio Appoints Telitacicept Development Expert Dr. Qing Zuraw as Chief Development Officer
Vor Bio has appointed Dr. Qing Zuraw as Chief Development Officer, bringing over 25 years of experience in autoimmune disease clinical development.
J&J Wins Federal Circuit Appeal, Preserves Invega Sustenna Patent Protection Until 2031
Johnson & Johnson successfully defended its Invega Sustenna schizophrenia drug patent against appeals from Teva and Viatris, maintaining market exclusivity until 2031.
Biocon Races to Launch First Generic Semaglutide in Canada as Wegovy Patents Expire
Biocon Ltd. is seeking regulatory approval for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting Canada as its first major market entry by 2026.
Teva Partners with Formycon to Commercialize Stelara Biosimilar Fymskina in Germany
Formycon AG has entered into a distribution agreement with Teva's subsidiary Ratiopharm for the semi-exclusive commercialization of its Stelara biosimilar FYB202, branded as Fymskina, in Germany.
Digital Inhaler Technology Shows Promise for Early COPD Exacerbation Detection
Digital inhalers can detect significant physiologic changes up to two weeks before COPD exacerbations occur, potentially enabling earlier clinical intervention.
Teva and Fosun Pharma Form Strategic Partnership for Novel Anti-PD1-IL2 Cancer Immunotherapy TEV-56278
Teva Pharmaceutical and Fosun Pharma announced a strategic partnership to develop TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy currently in Phase 1 trials for various cancers including melanoma.
Major PBMs Exclude Humira Biosimilars from 2025 Formularies, Favor Private-Label Products
The three largest U.S. pharmacy benefit managers have excluded nearly all marketed Humira biosimilars from their 2025 standard formularies, marking a dramatic shift from 2024 when eight products were covered.